Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,947 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-world progression-free survival and overall survival of palbociclib plus endocrine therapy (ET) in Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer in the first-line or second-line setting: an observational study.
Yoshinami T, Nagai SE, Hattori M, Okamura T, Watanabe K, Nakayama T, Masuda H, Tsuneizumi M, Takabatake D, Harao M, Yoshino H, Mori N, Yasojima H, Oshiro C, Iwase M, Yamaguchi M, Sangai T, Kosaka N, Tajima K, Masuda N. Yoshinami T, et al. Among authors: yamaguchi m. Breast Cancer. 2024 Apr 20. doi: 10.1007/s12282-024-01575-5. Online ahead of print. Breast Cancer. 2024. PMID: 38642245
Fulvestrant with or without anti-HER2 therapy in patients in a postmenopausal hormonal state and with ER-positive HER2-positive advanced or metastatic breast cancer: A subgroup analysis of data from the Safari study (JBCRG-C06).
Masuyama M, Masuda N, Kawaguchi H, Yamamoto Y, Saji S, Nakayama T, Aogi K, Anan K, Ohtani S, Sato N, Takano T, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamaguchi M, Yamashita T, Yotsumoto D, Toi M, Ohno S. Masuyama M, et al. Among authors: yamaguchi m. Cancer Med. 2023 Sep;12(17):17718-17730. doi: 10.1002/cam4.6390. Epub 2023 Aug 1. Cancer Med. 2023. PMID: 37525895 Free PMC article.
Retrospective study on the effectiveness of medroxyprogesterone acetate in the treatment of ER-positive/HER2-negative post-menopausal advanced breast cancer: an additional analysis of the JBCRG-C06 Safari study.
Kawaguchi H, Yamamoto Y, Saji S, Masuda N, Nakayama T, Aogi K, Anan K, Ohtani S, Sato N, Takano T, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamaguchi M, Yamashita T, Yotsumoto D, Toi M, Ohno S. Kawaguchi H, et al. Among authors: yamaguchi m. Jpn J Clin Oncol. 2023 Mar 7;53(3):203-211. doi: 10.1093/jjco/hyac184. Jpn J Clin Oncol. 2023. PMID: 36484305
Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and/or leptomeningeal disease (ROSET-BM).
Niikura N, Yamanaka T, Nomura H, Shiraishi K, Kusama H, Yamamoto M, Matsuura K, Inoue K, Takahara S, Kita S, Yamaguchi M, Aruga T, Shibata N, Shimomura A, Ozaki Y, Sakai S, Kiga Y, Izutani T, Shiosakai K, Tsurutani J. Niikura N, et al. Among authors: yamaguchi m. NPJ Breast Cancer. 2023 Oct 11;9(1):82. doi: 10.1038/s41523-023-00584-5. NPJ Breast Cancer. 2023. PMID: 37821514 Free PMC article.
[Studies on EDTA-dependent pseudoneutropenia].
Kobayashi S, Seki K, Yamaguchi M, Maruta A, Kodama F. Kobayashi S, et al. Among authors: yamaguchi m. Rinsho Ketsueki. 1991 Mar;32(3):205-11. Rinsho Ketsueki. 1991. PMID: 1904107 Japanese.
Response to the letter to the editor: clinical impact of non-lying time on hospital-associated functional decline in older patients undergoing transcatheter aortic valve implantation.
Kono Y, Mukaino M, Ozawa Y, Mizutani K, Senju Y, Ogasawara T, Yamaguchi M, Muramatu T, Izawa H, Otaka Y. Kono Y, et al. Among authors: yamaguchi m. Heart Vessels. 2024 Jun 3. doi: 10.1007/s00380-024-02419-0. Online ahead of print. Heart Vessels. 2024. PMID: 38829388 No abstract available.
5,947 results